Efficacy and safety of guselkumab in treating moderate-to-severe plaque psoriasis with inadequate response to other biologics
Objective To evaluate the efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis who exhibited inadequate response to other biologics.Methods A total of 14 patients were enrolled,including 9 males and 5 females,with a median age of 39.5 years and an average disease duration of(15.1±5.0)years.All patients previously undergone treatment with other biologics for at least 4 months,yet failed to achieve achieved psoriasis area and severity index(PASI)75 or lost PASI 75 during treatment.After switching to guselkumab treatment,the efficacy and adverse reactions of these patients were assessed at week 12 and week 20.Results After 12 weeks of treatment with guselkumab,the mean PASI score of 14 patients decreased from 8.0±3.6 at baseline to 1.7±1.4,with PASI 75/90 response rates of 85.7％and 35.7％,respectively.At week 20,the mean PASI score were 0.93±0.81,and the PASI75/90/100 response rate were 100％,57.1％and 7.1％,respectively.Fatigue was reported in 1 patient(7.14％),while two patients(14.29％)experienced upper respiratory tract infection.Conclusion Guselkumab showed significant efficacy in patients with moderate-to-severe plaque psoriasis who exhibited inadequate response to other biologics,while no serious adverse reactions were observed.
NETL
NSTL
万方数据
